{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IND.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.205,"timestamp":1741229097271,"preClose":0.195,"halted":0,"volume":63212,"delay":0,"changeRate":0.051282,"change":0.01,"floatShares":42536073,"shares":80322500,"eps":-0.024706,"lyrEps":-0.024706,"pbRate":5.88,"amount":12911,"amplitude":0.025641,"volumeRatio":0.374266,"dividePrice":0,"prevYearClose":0.16,"fiveDayClose":0.115,"twentyDayClose":0.12},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-31.33%","roe":"-58.38%","lyrEps":-0.024706,"volumeRatio":0.374266,"shares":80322500,"dividePrice":0,"high":0.205,"amplitude":0.025641,"preClose":0.195,"low":0.2,"week52Low":0.09,"pbRate":"5.88","psRate":"19672.77","week52High":0.325,"institutionHeld":0,"latestPrice":0.205,"committee":-0.836179,"eps":-0.024706,"divideRate":0,"volume":63212,"delay":0,"ttmEps":-0.024706,"open":0.205,"prevYearClose":0.16,"prevWeekClose":0.12,"prevMonthClose":0.12,"prevQuarterClose":0.16,"fiveDayClose":0.115,"twentyDayClose":0.12,"sixtyDayClose":0.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2467172814","title":"ImmuneOnco Launches Global Registrational Strategy for Anti-Tumor Drug with Instil","url":"https://stock-news.laohu8.com/highlight/detail?id=2467172814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467172814?lang=en_us&edition=fundamental","pubTime":"2024-09-16 20:08","pubTimestamp":1726488530,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  , in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer  and triple-negative breast cancer , a Monday bourse filing said.In China, ImmuneOnco is expediting the development of IMM2510/SYN-2510 in front-line NSCLC by targeting the start of a Phase 1b/2 front-line chemo combination study in late 2024. The company is also speeding up the development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies set to begin in early 2025.In the US, Instil plans to submit an investigational new drug  application for IMM2510/SYN-2510 for NSCLC and TNBC to the US Food & Drug Administration in late 2024, starting with a Phase 2 trial.Shares of the company closed over 35% higher on Monday.Price : $6.68, Change: $+1.7, Percent Change: +35.22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4585","BK4023","BK4588","BK4526","HKD","01541","BK7095","IND.AU"],"gpt_icon":0},{"id":"2465543968","title":"BRIEF-Immuron Plans Phase 2 Trial For Imm-529 Following FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2465543968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465543968?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:10","pubTimestamp":1725538259,"startTime":"0","endTime":"0","summary":"Immuron Ltd   :   * IMMURON PLANS PHASE 2 TRIAL FOR IMM-529 FOLLOWING FDA REVIEW   * IMMURON LTD - INVESTIGATIONAL NEW DRUG  APPLICATION FOR IMM-529 PLANNED FOR 1H 2025   * IMMURON - COMPLETES PRE-IND MEETING WITH FDA ON DEVELOPMENT OF IMM-529 AS PRODUCT TO SPECIFICALLY PREVENT OR TREAT CLOSTRIDIOIDES DIFFICILE INFECTIONSource text for Eikon:    Further company coverage:","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU","BK7508","IMC.AU","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":2,"totalSize":18}]}}